Traveller vaccination haemophilus influenzae type b: Difference between revisions
Usama Talib (talk | contribs) No edit summary |
No edit summary |
||
(One intermediate revision by the same user not shown) | |||
Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Traveller vaccination | {{Traveller vaccination}} | ||
{{CMG}};{{AE}}{{USAMA}} | {{CMG}};{{AE}}{{USAMA}} | ||
==Overview== | ==Overview== | ||
Line 9: | Line 9: | ||
recommendations. | recommendations. | ||
==Disease cause== | ==Disease cause== | ||
The bacterium | The bacterium [[haemophilus influenzae type b]] (Hib). | ||
==Transmission== | ==Transmission== | ||
Respiratory droplets. | Respiratory droplets. | ||
==Nature of the disease== | ==Nature of the disease== | ||
Important cause of pneumonia, meningitis, septicaemia, epiglottitis and other potential life-threatening infections primarily in children aged 3 months to 5 years. | Important cause of [[pneumonia]], [[meningitis]], [[septicaemia]], [[epiglottitis]] and other potential life-threatening infections primarily in children aged 3 months to 5 years. | ||
==Geographical distribution== | ==Geographical distribution== | ||
Prevalent in countries with low coverage of Hib vaccination. | Prevalent in countries with low coverage of Hib vaccination. |
Latest revision as of 18:47, 20 April 2017
Traveler Vaccination |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1];Associate Editor(s)-in-Chief: Usama Talib, BSc, MD [2]
Overview
Protection against Haemophilus influenzae type b (Hib) is not specific to the needs of travelling children. In many countries Hib vaccine is routinely administered in childhood. Missing vaccinations in travellers <5 years of age should be offered according to national recommendations.
Disease cause
The bacterium haemophilus influenzae type b (Hib).
Transmission
Respiratory droplets.
Nature of the disease
Important cause of pneumonia, meningitis, septicaemia, epiglottitis and other potential life-threatening infections primarily in children aged 3 months to 5 years.
Geographical distribution
Prevalent in countries with low coverage of Hib vaccination.
Risk for travellers
The risk is likely to be increased in an environment of low Hib vaccination coverage.
Vaccine
Polysaccharide-protein conjugate vaccine. In infants 2 or 3 primary doses should be administered, the first dose at 6 weeks of age or soon thereafter. Hib vaccine is not required for healthy children older than 5 years.